OncLiveNumerous Drug Classes Studied for Use in Follicular LymphomaOncLiveOfatumumab, a humanized monoclonal anti-CD20 antibody approved under the trade name Arzerra for use in chronic lymphocytic leukemia (CLL), has shown some promise as a single agen…
|
Is Chronic Fatigue Syndrome an Autoimmune Disease?
Blogcritics.org (blog) In 2007 Øystein Fluge and Olav Mella, two Norwegian oncologists at Haukeland University Hospital in Bergen, Norway, accidentally discovered that rituximab, a drug employed to treat Hodgkin’s lymphoma (as well as autoimmune disorders such as … |
 TopNews Arab Emirates |
Lower Darwen mum calls on government to protect cancer drugs fund
Lancashire Telegraph The Rarer Cancers Foundation said treatments to be removed from the approved list include rituximab, used to treat blood cancers, alemtuzumab, for leukaemia sufferers, and erlotinib, used to treat lung cancer. Chief executive Andrew Wilson said: “The … Cancer patients facing race against clock for drugs in fund ‘betrayal’Telegraph.co.uk The great cancer betrayal: Number of treatments on approved list for patients …Daily Mail |
|
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …
EON: Enhanced Online News (press release) “Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an … |
The Wild Story Behind A Promising Experimental Cancer DrugForbesIn 1997, IDEC delivered rituximab, the first monoclonal antibody approved by the FDA for cancer treatment; it is also used for the treatment of rheumatoid arthritis. IDEC merged with Bioge…
RPT-BRIEF-Emergent Biosolutions to expand clinical trial of TRU-016 and …ReutersApril 5 (Reuters) – April 5 (Reuters) – Emergent Biosolutions Inc : * To expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment …
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …Fort Mills TimesEmergent BioSolutions Inc. (NYSE: EBS) today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol …
|
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …
MarketWatch (press release) “Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an … |
|
Hospitals to get tough on smoking relatives, potential cure for insomnia and …
Pulse Drugs no longer listed include rituximab for blood cancers, alemtuzumab for leukaemia, erlotinib for lung cancer, trabectedin for ovarian cancer and plerixafor for myeloma. With such perplexing news, it’s heartening to hear the Daily Mail has … |
 Telegraph.co.uk |
Cancer patients facing race against clock for drugs in fund ‘betrayal’
Telegraph.co.uk Drugs which are not on the central list include rituximab for blood cancers, one of the most commonly requested treatments under the previous fund, as well as alemtuzumab for leukaemia, erlotinib for lung cancer, trabectedin for ovarian cancer, and … The great cancer betrayal: Number of treatments on approved list for patients …Daily Mail |